How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Immunogenicity Testing Service Market
- By Assay Type: Enzyme-Linked Immunosorbent Assay (ELISA), Electrochemiluminescence (ECL) Assay, Surface Plasmon Resonance (SPR), Radioimmunoassay (RIA), Cell-Based Neutralizing Antibody Assay
- By Service Model: Contract Research Organization (CRO) Services, In-house Testing Services, Hybrid Service Model
- By End User: Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Academic and Research Institutes, Diagnostic Laboratories
- By Therapeutic Area: Monoclonal Antibodies, Vaccines, Gene Therapy, Recombinant Proteins, Cell Therapy
- By Sample Type: Serum Samples, Plasma Samples, Cell Culture Supernatants, Tissue Samples
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Enzyme-Linked Immunosorbent Assay (ELISA) leads By Assay Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 17 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 301 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.179 →
- 12 Company Profiles 17 players: SWOT & benchmarking p.187 →
Full report · locked preview
Everything inside the Immunogenicity Testing Service Market report
A complete, evidence-based study - 12 chapters and 126 sections covering market size, segmentation across 5 axes, regional analysis and 17 company profiles, forecast to 2033.
Segmentation covered
Assay Type 5
Service Model 3
End User 4
Therapeutic Area 5
Sample Type 4
Companies profiled
Charles River Laboratories International Inc.
Eurofins Scientific
Covance Inc. (LabCorp)
ICON plc
PPD
Inc. (Thermo Fisher Scientific)
WuXi AppTec
BioAgilytix Labs
Q2 Solutions
SGS SA
Parexel International Corporation
Syneos Health
+5 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
17 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Charles River Laboratories International Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Eurofins Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Covance Inc. (LabCorp)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →ICON plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →PPD
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Inc. (Thermo Fisher Scientific)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →WuXi AppTec
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →BioAgilytix Labs
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Q2 Solutions
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →SGS SA
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Parexel International Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Syneos Health
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Frontage Laboratories Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.227 →Labcorp Drug Development
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Catalent Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Medpace
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.250 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$9,031M by 2033 · 11.0% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Enzyme-Linked Immunosorbent Assay (ELISA)48.7
- Electrochemiluminescence (ECL) Assay19.6
- Surface Plasmon Resonance (SPR)8.6
- Radioimmunoassay (RIA)9.9
- Cell-Based Neutralizing Antibody Assay13.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,297M → $2,851M · 10.3%
Europe$903.9M → $1,864M · 9.5%
Asia Pacific$825.3M → $1,805M · 10.3%
Latin America$510.9M → $1,211M · 11.4%
Middle East and Africa$393.0M → $951.2M · 11.7%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.912026
10.922027
10.942028
10.942029
10.962030
10.982031
10.992032
10.992033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Charles River Laboratories International Inc.16.5
- Eurofins Scientific21.6
- Covance Inc. (LabCorp)12.8
- ICON plc5.1
- PPD7.5
- Inc. (Thermo Fisher Scientific)8.5
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Assay Type23.4%
Service Model28.5%
End User8.8%
Therapeutic Area26.5%
Sample Type12.8%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.8
- Europe21.5
- Asia Pacific20.8
- Latin America13.9
- Middle East and Africa11.0
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Charles River Laboratories International Inc. | 94 | 75 | 73 | 79 | 74 | 79 | 79 |
| Eurofins Scientific | 71 | 81 | 86 | 87 | 87 | 84 | 83 |
| Covance Inc. (LabCorp) | 67 | 67 | 74 | 70 | 88 | 69 | 73 |
| ICON plc | 78 | 73 | 73 | 74 | 73 | 79 | 75 |
| PPD | 54 | 54 | 61 | 57 | 58 | 63 | 58 |
| Inc. (Thermo Fisher Scientific) | 68 | 68 | 69 | 53 | 54 | 60 | 62 |
| WuXi AppTec | 49 | 55 | 51 | 47 | 52 | 55 | 52 |
| BioAgilytix Labs | 55 | 53 | 56 | 52 | 37 | 57 | 52 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Charles River Laboratories International Inc.
- Eurofins Scientific
- Covance Inc. (LabCorp)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Charles River Laboratories International Inc. | ✓ | ✓ | − | ◐ | ◐ | ◐ |
| Eurofins Scientific | ✓ | ✓ | ✓ | ◐ | ✓ | ✓ |
| Covance Inc. (LabCorp) | − | − | ◐ | ◐ | ✓ | ✓ |
| ICON plc | ✓ | ✓ | ◐ | ◐ | ◐ | ◐ |
| PPD | ◐ | − | − | ◐ | ◐ | ◐ |
| Inc. (Thermo Fisher Scientific) | ✓ | ◐ | ✓ | ◐ | ◐ | ◐ |
| WuXi AppTec | − | − | − | − | − | ◐ |
| BioAgilytix Labs | − | ◐ | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Eurofins Scientific83
2Charles River Laboratories International Inc.79
3ICON plc75
4Covance Inc. (LabCorp)73
5Inc. (Thermo Fisher Scientific)62
6PPD58
7WuXi AppTec52
8BioAgilytix Labs52
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Charles River Laboratories International Inc.Eurofins Scientific
Challenger2
Strong scale, closing on the leaders.
Covance Inc. (LabCorp)ICON plc
Contender2
Focused players with pockets of strength.
PPDInc. (Thermo Fisher Scientific)
Niche2
Specialists in a single segment or region.
WuXi AppTecBioAgilytix Labs
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Assay Type in North America, then scale across Immunogenicity Testing Service Market — a $449M beachhead inside a $6.85B market.
Beachhead (SOM)$449Mobtainable near-term
Serviceable (SAM)$2.83Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion86 fit
Enzyme-Linked Immunosorbent Assay (ELISA)
Best fit — highest urgency & budget in Assay Type.
Economic buyer78 fit
Electrochemiluminescence (ECL) Assay
Strong fit — clear ROI and a fast path to value.
End user67 fit
Surface Plasmon Resonance (SPR)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Assay Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Service Model & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel28%
Digital / self-serve21%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Assay Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Immunogenicity Testing Service Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified42%
Sales qualified23%
Evaluation11%
Closed-won8%
$13.2KCAC
$47KLTV
3.5:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Immunogenicity Testing Service Market is a resilient opportunity — $1.94B by 2033, compounding at 5.0%.
TAM · 2025$1.32Btoday
TAM · 2033$1.94Bforecast
CAGR5.0%2027–2033
Cumulative$14.5Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$1.94BTotal addressable market
SAM$753MServiceable available market
SOM$149MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →5.0% CAGR
Demand compounds through 2033, outpacing GDP across Assay Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Assay Type moving from early to mainstream — durable secular demand.
Consolidation upside
17+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$1.94BLarge & growingTAM by 2033 at 5.0% CAGR
$753MServiceable nowreachable with today’s model
$149MBeachhead winobtainable near-term share
17+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.52BBear3.2% CAGR
$1.94BBase5.0% CAGR
$2.49BBull6.6% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Service Model optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Immunogenicity Testing Service Market — a $4.94B market by 2033. Plan: grow share from 6.5% to 12.2%.
Market size · 2033$4.94Btotal addressable
Market CAGR8.0%2027–2033
Target share12.2%from 6.5% today
Revenue ambition$602Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.5% | 12.2% | Ahead |
| Revenue | $336M | $602M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Behind |
| Gross margin | 28.8% | 38.0% | At risk |
| Customer retention | 87.0% | 96.0% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Assay Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Service Model capability
A defensible second engine — invest in Service Model to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Assay Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Service Model
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $89M capacity & capability investment
- Greenlight bolt-on M&A in Service Model
- Authorise North America expansion plan
- Fund R&D program for Assay Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossBehind
- Input-cost & supply riskOn track
- Regulatory / policy changeBehind
- Execution & talentBehind
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Immunogenicity Testing Service Market conversation — a $4.57B market you can size, segment and defend in minutes.
Market size · 2033$4.57Btotal opportunity
Growth8.4%CAGR to 2033
Addressable buyers966+accounts in scope
Typical ROI5.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Assay Type
Goal Grow share in Assay Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.5×return on cost, year one
< 3 mopayback period
$42K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
17+players profiled in this market
Coverage includes
Charles River Laboratories International Inc.Eurofins ScientificCovance Inc. (LabCorp)ICON plcPPDInc. (Thermo Fisher Scientific)WuXi AppTecBioAgilytix Labs+9 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Immunogenicity Testing Service Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Immunogenicity Testing Service Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Immunofluorescence Reagents Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportImmunofluorescence Quantitative Analyzers Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportImmunofluorescence Microscopy Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportImmunofluorescence (IF) Reagents Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportImmunoelectrochemical Analyzer Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportImmunodiagnostic Equipment Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportImmunodiagnostic Device and Reagent Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportImmunodeficient Mouse Models Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportImmunocytochemistry Reagents Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportImmunochromogenic Kit Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportImmunochromato Test Reader Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportImmunochromato Reader Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.